Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
IPO Year: 2021
Exchange: NASDAQ
Website: alzamend.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/1/2021 | $8.00 | Buy | Ascendiant Capital Markets |
S-1/A - Alzamend Neuro, Inc. (0001677077) (Filer)
DEFA14A - Alzamend Neuro, Inc. (0001677077) (Filer)
DEFA14A - Alzamend Neuro, Inc. (0001677077) (Filer)
DEF 14A - Alzamend Neuro, Inc. (0001677077) (Filer)
S-3 - Alzamend Neuro, Inc. (0001677077) (Filer)
10-Q - Alzamend Neuro, Inc. (0001677077) (Filer)
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
PRE 14A - Alzamend Neuro, Inc. (0001677077) (Filer)
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen
ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with Alzheimer's in the fourth quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration with Massachusetts General Hospital as its contract r
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with MDD in the fourth quarter of 2025. This study follows t
ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with PTSD in the fourth quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration with Massachusetts General Hospital as its contract research
ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with BD, which is expected to commence in the third quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration with Massachusetts General Hos
ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced its plans to initiate the first of five highly anticipated phase II clinical studies of AL001, with the first study, in healthy human subjects, expected to commence in the second quarter of 2025. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration w
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy, Alzheimer's disease, BD, MDD, and PTSD subjects Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the completion of a groundbreaking head coil by Tesla Dynamic Coils BV ("Tesla"). The development of the head coil was necessary to facilitate the five upcoming
Company to report on progress with clinical trials to be initiated in 2025 and expected milestones Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it will be presenting at the Sequire Investor Summit, a three-day investor conference that is being held from January 21-23, 2025 at the Condado Vanderbilt in Puerto Rico. Stephan Jackman, Alzamend's Chief Executive Officer, will be presenting at 11:30 a.m. ET on January 22, 2025, t
Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder and Post-Traumatic Stress Disorder Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced it will have a poster presentation at the Society of Toxicology ("SOT") Annual Meeting and ToxExpo, being held from March 16-20,
During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash Strengthened balance sheet in preparation for five clinical trials to be initiated in 2025 Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), reported its financial results for the second quarter ended October 31, 2024, which were disclosed on a quarterly
Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and marketed lithium therapies At a low dose, AL001 evidenced consistently higher lithium concentrations than lithium carbonate within critical brain regions comprising target tissue for efficacy, which may provide therapeutic benefits with less risk in multiple neurological disorders Data will guide upcoming "Lithium in Brain" Phase II clinical trials in partnership with Massachusetts General Hospital Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment o
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
5 - Alzamend Neuro, Inc. (0001677077) (Issuer)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the third quarter ended September 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Third quarter 2022 highlights include: Total assets of $610.9 million as of September 30, 2022; Positive working capital of $25.7 million as of September 30, 2022; Cash and cash equivalents of $10.1 million as of September 30, 2022; Revenue from cryptocurrency mining of $3.9 million, compared to $0.3 million in the prior third fiscal quarter; Revenue from the Company's majority owned subsidiary, The Singing Machine Company, Inc. (NASDAQ:MICS)
BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the second quarter ended June 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Second quarter 2022 highlights include: Total assets of $596.3 million as of June 30, 2022; Positive working capital of $51.4 million as of June 30, 2022; Cash and cash equivalents of $24.1 million as of June 30, 2022; Revenue from cryptocurrency mining of $4.0 million, compared to $0.3 million in the prior second fiscal quarter; Revenue from hotel operations of $4.6 million, compared to $0 in the prior second fiscal quarter; Revenue from lendi
The Company Grows Revenue by 120% to $52 Million and Ends the Year with $490 Million in Assets BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") today announced its financial results for the year ended December 31, 2021 contained within its Form 10‑K filed with the Securities and Exchange Commission. Year ended December 31, 2021 highlights: Revenue of $52.4 million, an increase of 120% from $23.9 million in the prior fiscal year; Revenue from lending and trading activities of $16.9 million due to the allocation of capital to Digital Power Lending, LLC ("DP Lending"); Revenue from trading activities during the year ended December 31, 2021
IND Submission for Combined AL002 Phase 1/2 Clinical Trial Expected in Second Quarter of 2022 Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received confirmation that topline data for its Phase 1 clinical trial for AL001 for dementia related to Alzheimer's will be delivered mid- to late-December 2021. The Phase 1 first-in-human study is for the purpose of determining potential clinically safe and appropriate dosing for AL001 in a planned Phase 2 multiple ascending dose study. AL001 is a lithium-deliv
Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), today announced its financial results for the three and nine months ended September 30, 2021. Nine months ended September 30, 2021 highlights: Revenue of $44.6 million, an increase of 167% from $16.7 million in the prior nine-month period; Revenue from lending and trading activities of $19.6 million due to the allocation of capital to DP Lending; Revenues from our trading activities during the nine months ended September 30, 2021 included significant net gains on equity securities, including unrealized gains and losses from market price changes. These gains and losses have caused and will continue to
Q2 2021 Revenue of $62.1 Million, up 1050% From the Prior Year's Quarter Q2 2021 Net Income of $42.2 Million Compared to a $1.4 Million Loss in the Prior Year's Quarter Total Assets of More Than a Quarter of a Billion Dollars ($259.1 Million) Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), today announced its financial results for the second quarter ended June 30, 2021. Q2-2021 highlights Revenue of $62.1 million, an increase of 1050% from $5.4 million in the prior second fiscal quarter; Revenue from lending and trading activities of $53.3 million due to the allocation of capital to the Company's wholly owned subsidiary, Digital Power Lending, LL
Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00